このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Allogeneic iNKT Cells in AS: Immune Remodeling Study

2026年11月16日 更新者:Jian Zhu、Chinese PLA General Hospital

An Observational Exploratory Study of Immune Remodeling in Patients With Ankylosing Spondylitis After Multiple Infusions of Allogeneic iNKT Cells

This study observes patients with ankylosing spondylitis (AS) who are receiving, or have received, multiple infusions of allogeneic invariant natural killer T (iNKT) cells as a treatment. Allogeneic iNKT cells are immune cells taken from a healthy donor, grown in the laboratory, and given to patients by infusion.

The treatment infusions are given under a separate treatment protocol. This study does not give any treatment. It only collects blood samples and analyzes them to learn how the immune system changes during and after the cell infusions.

Researchers will study two main questions: (1) how iNKT cell subsets and the overall immune cell network in the blood change over time, and (2) what the iNKT cells look like at the single-cell level, including their transcriptional (gene expression) profiles and clonal evolution..

Participants will provide blood samples at scheduled study visits for up to 52 weeks. The goal is to better understand how allogeneic iNKT cell therapy reshapes the immune system in AS, which may help guide future treatment studies.

調査の概要

状態

まだ募集していません

研究の種類

観察的

入学 (推定)

12

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

      • Beijing、中国
        • Chinese PLA General Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

Adults with a diagnosis of ankylosing spondylitis who are receiving or have received multiple infusions of allogeneic iNKT cells under a treatment protocol.Participants are enrolled from the same institution where the treatment is administered and are followed prospectively for longitudinal assessment of immune remodeling.

説明

Inclusion Criteria:

  1. Participants must be able to understand the informed consent form and voluntarily agree to participate, with a signed and dated informed consent form.
  2. Age 18 to 65 years (inclusive), both sexes.
  3. Diagnosis of ankylosing spondylitis (AS) according to the 1984 modified New York criteria, and classification as axial spondyloarthritis (axSpA) according to the 2025 ASAS-SPARTAN axSpA classification criteria. Participants must have active disease, meeting both of the following criteria: (a) Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score >= 4; and (b) spinal pain score >= 4 as measured by BASDAI question 2.
  4. Prior treatment with at least 2 nonsteroidal anti-inflammatory drugs (NSAIDs) at full dose on a regular schedule for at least 4 weeks, with no significant improvement in symptoms as assessed by the investigator; or intolerance to NSAIDs (discontinuation of NSAID treatment due to treatment-related adverse events, such as allergic reactions or gastrointestinal signs or symptoms; the 4-week treatment duration requirement does not apply in this case); or contraindication to NSAID treatment.
  5. Participants who have received no more than 1 prior biologic agent or JAK inhibitor (agents with the same generic name count as 1): treatment must have been administered at the recommended dose for at least 12 weeks with inadequate response, intolerance (adverse events leading to discontinuation), or inability to continue for other reasons. Washout periods before the first dose: etanercept, 4 weeks; infliximab, 8 weeks; adalimumab, certolizumab pegol, or golimumab, 10 weeks; IL-17 inhibitors, 12 weeks; JAK inhibitors, 4 weeks; biologic classes not listed, 5 drug half-lives.
  6. If participants are receiving methotrexate (MTX), sulfasalazine (SSZ), or hydroxychloroquine (HCQ), the treatment duration before enrollment must be at least 3 months, and the dose must have been stable for at least 4 weeks.
  7. Participants of childbearing potential must use at least 1 medically accepted contraceptive method during the study treatment period and for 6 months after the end of study treatment. Serum human chorionic gonadotropin (HCG) must be negative within 7 days before the first dose for women of childbearing potential; participants must be non-lactating and non-pregnant.
  8. Able to communicate well with the investigator and comply with the requirements of the study.

Exclusion Criteria:

  1. Allergy to immunotherapy or to the excipients of the investigational drug.
  2. Known or suspected history of complete spinal ankylosis, or complete spinal ankylosis confirmed clinically and radiographically.
  3. Complete ankylosis of the sacroiliac joints.
  4. Spinal or joint surgery within 2 months before dosing, or planned spinal or joint surgery during the study period.
  5. Other untreated malignancy within the past 5 years or concomitant malignancy, except adequately treated skin basal cell carcinoma, carcinoma in situ, and breast cancer with no recurrence for more than 3 years after curative surgery.
  6. Any active, known, or suspected autoimmune disease other than the indication under study (including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, vasculitis, glomerulonephritis, uveitis, hypophysitis, and hyperthyroidism). Exceptions: type 1 diabetes mellitus on stable-dose insulin therapy for at least 3 months before enrollment; hypothyroidism requiring only hormone replacement therapy; and skin conditions (such as eczema, vitiligo, or psoriasis) requiring no systemic treatment and without acute exacerbation within 1 year before screening.
  7. Severe trauma or major surgery (such as transabdominal or transthoracic surgery) within 6 months before screening, or planned major surgery during the study.
  8. History of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis (may be enrolled if only detected on imaging and no corticosteroid treatment is required), or drug-induced pneumonitis.
  9. Poorly controlled cardiac signs, symptoms, or diseases: (a) congestive heart failure of NYHA class II or above; b) unstable angina within 6 months; (c) acute myocardial infarction within 1 year; (d) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (such as QTc > 450 msec in males or > 470 msec in females).
  10. Hypertension not well controlled by antihypertensive medication (systolic blood pressure >= 140 mmHg or diastolic blood pressure >= 90 mmHg within 7 days before enrollment).
  11. Cerebrovascular or cardiovascular events within 3 months before dosing (myocardial infarction, ischemic or hemorrhagic stroke excluding lacunar infarction, deep vein thrombosis, etc.).
  12. Any of the following at screening or baseline: (a) aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN; (b) serum creatinine > 1.5 x ULN or glomerular filtration rate < 60 mL/min/1.73 m2; (c) activated partial thromboplastin time (APTT) > 1.5 x ULN or prothrombin time (PT) > 2.5 x ULN (without anticoagulant therapy); (d) left ventricular ejection fraction <= 50%; (e) urine protein > 2+ on urinalysis within 7 days before enrollment, confirmed by 24-hour urine protein quantification > 1.0 g; (f) white blood cell count < 3 x 10^9/L, hemoglobin < 90 g/L, absolute neutrophil count < 1.5 x 10^9/L, or platelet count < 90 x 10^9/L.
  13. Any of the following bleeding conditions: bleeding events of CTCAE v6.0 grade 2 or above within 4 weeks before enrollment; gastrointestinal bleeding history or definite gastrointestinal bleeding within 6 months before enrollment, or bleeding from esophageal and/or gastric varices without endoscopic or transjugular intrahepatic portosystemic shunt prophylaxis; known hereditary or acquired bleeding or thrombotic tendency (such as hemophilia or coagulation disorders).
  14. Systemic active infection requiring treatment within 2 weeks before enrollment, or unexplained fever with temperature >= 38.5 degrees C within 7 days before enrollment.
  15. Congenital or acquired immunodeficiency (such as HIV infection); active syphilis infection; positive tuberculosis test.
  16. HBV or HCV infection at screening with viral load above the lower limit of detection (HBV DNA >= 10 IU/mL or HCV RNA >= 10 IU/mL).
  17. Prior receipt of genetically modified cell therapy, or receipt of non-genetically modified cell therapy within 6 months before screening.
  18. Prior use of oral glucocorticoids, or receipt of glucocorticoids by any intra-articular, intramuscular, or intravenous injection.
  19. Receipt of disease-modifying antirheumatic drugs (DMARDs) other than sulfasalazine and hydroxychloroquine within 1 month before dosing; leflunomide discontinued for less than 8 weeks; or discontinuation for less than 5 drug half-lives according to the actual drug class (i.e., the DMARD washout period should exceed 5 half-lives of the corresponding drug), whichever is longer.
  20. Current use of strong opioid analgesics (such as methadone, hydromorphone, or morphine).
  21. Vaccination with live or attenuated vaccines within 4 weeks before screening.
  22. Enrollment in another clinical study of a drug or device within 4 weeks before screening.
  23. Other factors judged by the investigator that may lead to premature study termination, such as other serious concomitant diseases (including severe diabetes, thyroid disease, spinal cord compression, superior vena cava syndrome, or psychiatric illness), severe laboratory abnormalities, or family or social factors that may affect participant safety or the collection of data and samples.
  24. Intolerance to venipuncture, or history of needle or blood phobia.
  25. History of alcoholism, drug abuse, or use of any illicit drugs.
  26. Other factors considered by the investigator to be unsuitable for enrollment or likely to affect participant participation or completion of the study.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Ankylosing Spondylitis Cohort

Patients with ankylosing spondylitis who are receiving or have received multiple infusions of allogeneic invariant natural killer T (iNKT) cells under a treatment protocol. Participants are followed prospectively for assessment of immune remodeling.

Ex vivo expanded allogeneic invariant natural killer T (iNKT) cells administered by infusion under a separate treatment protocol. This study observes participants receiving this treatment; infusions are not administered by this observational study. Data collected include peripheral blood immune cell phenotyping and single-cell transcriptomic analysis to assess immune remodeling.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
Change in Peripheral Blood iNKT Cell Subset Polarization During Multiple Infusions of Allogeneic iNKT Cells
時間枠:Up to 52 weeks
Up to 52 weeks
Change in Peripheral Blood Immune Network Remodeling During Multiple Infusions of Allogeneic iNKT Cells
時間枠:Up to 52 weeks
Up to 52 weeks

二次結果の測定

結果測定
時間枠
Single-Cell Transcriptomic Signatures of iNKT Cells During Multiple Infusions of Allogeneic iNKT Cells
時間枠:Up to 52 weeks
Up to 52 weeks
Clonal Evolution of iNKT Cells During Multiple Infusions of Allogeneic iNKT Cells
時間枠:Up to 52 weeks
Up to 52 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月1日

一次修了 (推定)

2028年4月16日

研究の完了 (推定)

2028年4月16日

試験登録日

最初に提出

2026年11月16日

QC基準を満たした最初の提出物

2026年11月16日

最初の投稿 (実際)

2026年11月20日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月20日

QC基準を満たした最後の更新が送信されました

2026年11月16日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する